Evidence for the involvement of calbindin D28k in the presenilin 1 model of Alzheimer's disease

Neuroscience

Volumn 169, Issue 1, 2010, Pages 532-543

  Odero, G L ^a   Oikawa, K ^a   Glazner, K A C ^a,b   Schapansky, J ^a,b   Grossman, D ^a   Thiessen, J D ^a,b,c   Motnenko, A ^a   Ge, N ^a   Martin, M ^b,c   Glazner, G W ^a,b   Albensi, B C ^a,b  

^a St Boniface Research Centre   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF WINNIPEG   (Canada)

Author keywords

Alzheimer's disease; Calbindin D28k; Calcium; Hippocampus; Memory; Synaptic plasticity

Indexed keywords

CALBINDIN; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; LONG TERM POTENTIATION; MAZE TEST; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SPATIAL MEMORY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; EXCITATORY POSTSYNAPTIC POTENTIALS; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; LONG-TERM POTENTIATION; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; POINT MUTATION; PRESENILIN-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 77953808196     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.04.004     Document Type: Article

References (72)

1. Akbari Y., Hitt B.D., Murphy M.P., Dagher N.N., Tseng B.P., Green K.N., Golde T.E., LaFerla F.M. Presenilin regulates capacitative calcium entry dependently and independently of gamma-secretase activity. Biochem Biophys Res Commun 2004, 322:1145-1152.
2. Albensi B.C., Mattson M.P. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 2000, 35:151-159.
3. Albensi B.C., Alasti N., Mueller A.L. Long-term potentiation in the presence of NMDA receptor antagonist arylalkylamine spider toxins. J Neurosci Res 2000, 62:177-185.
4. Balschun D., Wolfer D.P., Bertocchini F., Barone V., Conti A., Zuschratter W., Missiaen L., Lipp H.P., Frey J.U., Sorrentino V. Deletion of the ryanodine receptor type 3 (RyR3) impairs forms of synaptic plasticity and spatial learning. EMBO J 1999, 18:5264-5273.
5. Barrow P.A., Empson R.M., Gladwell S.J., Anderson C.M., Killick R., Yu X., Jefferys J.G., Duff K. Functional phenotype in transgenic mice expressing mutant human presenilin-1. Neurobiol Dis 2000, 7:119-126.
6. Bliss T.V., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
7. Brody D.L., Holtzman D.M. Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury. Exp Neurol 2006, 197:330-340.
8. Brunkan A.L., Goate A.M. Presenilin function and gamma-secretase activity. J Neurochem 2005, 93:769-792.
9. Chan S.L., Mayne M., Holden C.P., Geiger J.D., Mattson M.P. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem 2000, 275:18195-18200.
10. Chan S.L., Furukawa K., Mattson M.P. Presenilins and APP in neuritic and synaptic plasticity: implications for the pathogenesis of Alzheimer's disease. Neuromolecular Med 2002, 2:167-196.
11. Chard P.S., Jordan J., Marcuccilli C.J., Miller R.J., Leiden J.M., Roos R.P., Ghadge G.D. Regulation of excitatory transmission at hippocampal synapses by calbindin d28k. Proc Natl Acad Sci U S A 1995, 92:5144-5148.
12. Cheung K.H., Shineman D., Muller M., Cardenas C., Mei L., Yang J., Tomita T., Iwatsubo T., Lee V.M., Foskett J.K. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron 2008, 58:871-883.
13. Chui D.H., Tanahashi H., Ozawa K., Ikeda S., Checler F., Ueda O., Suzuki H., Araki W., Inoue H., Shirotani K., Takahashi K., Gallyas F., Tabira T. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 1999, 5:560-564.
14. D'Hooge R., De Deyn P.P. Applications of the morris water maze in the study of learning and memory. Brain Res Brain Res Rev 2001, 36:60-90.
15. Drouet B., Pincon-Raymond M., Chambaz J., Pillot T. Molecular basis of Alzheimer's disease. Cell Mol Life Sci 2000, 57:705-715.
16. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383:710-713.
17. Duff K. Alzheimer transgenic mouse models come of age. Trends Neurosci 1997, 20:279-280.
18. Dumas T.C., Powers E.C., Tarapore P.E., Sapolsky R.M. Overexpression of calbindin d(28k) in dentate gyrus granule cells alters mossy fiber presynaptic function and impairs hippocampal-dependent memory. Hippocampus 2004, 14:701-709.
19. Fan Y., Shi L., Gu Y., Zhao Y., Xie J., Qiao J., Yang G.Y., Wang Y., Lu C.Z. Pretreatment with PTD-calbindin d 28k alleviates rat brain injury induced by ischemia and reperfusion. J Cereb Blood Flow Metab 2007, 27:719-728.
20. Fujii S., Matsumoto M., Igarashi K., Kato H., Mikoshiba K. Synaptic plasticity in hippocampal CA1 neurons of mice lacking type 1 inositol-1,4,5-trisphosphate receptors. Learn Mem 2000, 7:312-320.
21. Futatsugi A., Kato K., Ogura H., Li S.T., Nagata E., Kuwajima G., Tanaka K., Itohara S., Mikoshiba K. Facilitation of NMDAR-independent LTP and spatial learning in mutant mice lacking ryanodine receptor type 3. Neuron 1999, 24:701-713.
22. Goodman J.H., Wasterlain C.G., Massarweh W.F., Dean E., Sollas A.L., Sloviter R.S. Calbindin-d28k immunoreactivity and selective vulnerability to ischemia in the dentate gyrus of the developing rat. Brain Res 1993, 606:309-314.
23. Green K.N., Steffan J.S., Martinez-Coria H., Sun X., Schreiber S.S., Thompson L.M., LaFerla F.M. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci 2008, 28:11500-11510.
24. Green K.N., Demuro A., Akbari Y., Hitt B.D., Smith I.F., Parker I., LaFerla F.M. Serca pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol 2008, 181:1107-1116.
25. Guo Q., Fu W., Sopher B.L., Miller M.W., Ware C.B., Martin G.M., Mattson M.P. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 1999, 5:101-106.
26. Guo Q., Sebastian L., Sopher B.L., Miller M.W., Glazner G.W., Ware C.B., Martin G.M., Mattson M.P. Neurotrophic factors [activity-dependent neurotrophic factor (adnf) and basic fibroblast growth factor (bfgf)] interrupt excitotoxic neurodegenerative cascades promoted by a ps1 mutation. Proc Natl Acad Sci U S A 1999, 96:4125-4130.
27. Hilton G.D., Ndubuizu A., Nunez J.L., McCarthy M.M. Simultaneous glutamate and GABA(A) receptor agonist administration increases calbindin levels and prevents hippocampal damage induced by either agent alone in a model of perinatal brain injury. Brain Res Dev Brain Res 2005, 159:99-111.
28. Hof P.R., Morrison J.H. Neocortical neuronal subpopulations labeled by a monoclonal antibody to calbindin exhibit differential vulnerability in Alzheimer's disease. Exp Neurol 1991, 111:293-301.
29. Huang X.G., Yee B.K., Nag S., Chan S.T., Tang F. Behavioral and neurochemical characterization of transgenic mice carrying the human presenilin-1 gene with or without the leucine-to-proline mutation at codon 235. Exp Neurol 2003, 183:673-681.
30. Janus C., D'Amelio S., Amitay O., Chishti M.A., Strome R., Fraser P., Carlson G.A., Roder J.C., St George-Hyslop P., Westaway D. Spatial learning in transgenic mice expressing human presenilin 1 (ps1) transgenes. Neurobiol Aging 2000, 21:541-549.
31. Janus C. Search strategies used by app transgenic mice during navigation in the morris water maze. Learn Mem 2004, 11:337-346.
32. Jimenez-Escrig A., Gomez-Tortosa E., Baron M., Rabano A., Arcos-Burgos M., Palacios L.G., Yusta A., Anta P., Perez I., Hierro M., Munoz D.G., Barquero S. A multigenerational pedigree of late-onset Alzheimer's disease implies new genetic causes. Brain 2005, 128:1707-1715.
33. Jouvenceau A., Potier B., Poindessous-Jazat F., Dutar P., Slama A., Epelbaum J., Billard J.M. Decrease in calbindin content significantly alters ltp but not NMDA receptor and calcium channel properties. Neuropharmacology 2002, 42:444-458.
34. Kobayashi D.T., Chen K.S. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav 2005, 4:173-196.
35. Kouzu Y., Moriya T., Takeshima H., Yoshioka T., Shibata S. Mutant mice lacking ryanodine receptor type 3 exhibit deficits of contextual fear conditioning and activation of calcium/calmodulin-dependent protein kinase II in the hippocampus. Brain Res Mol Brain Res 2000, 76:142-150.
36. Lazarov O., Peterson L.D., Peterson D.A., Sisodia S.S. Expression of a familial Alzheimer's disease-linked presenilin-1 variant enhances perforant pathway lesion-induced neuronal loss in the entorhinal cortex. J Neurosci 2006, 26:429-434.
37. Leissring M.A., Yamasaki T.R., Wasco W., Buxbaum J.D., Parker I., LaFerla F.M. Calsenilin reverses presenilin-mediated enhancement of calcium signaling. Proc Natl Acad Sci U S A 2000, 97:8590-8593.
38. Lindner M.D., Plone M.A., Schallert T., Emerich D.F. Blind rats are not profoundly impaired in the reference memory Morris water maze and cannot be clearly discriminated from rats with cognitive deficits in the cued platform task. Brain Res Cogn Brain Res 1997, 5:329-333.
39. Lindner M.D. Reliability, distribution, and validity of age-related cognitive deficits in the morris water maze. Neurobiol Learn Mem 1997, 68:203-220.
40. Link C.D. Invertebrate models of Alzheimer's disease. Genes Brain Behav 2005, 4:147-156.
41. Lipp H.P., Wolfer D.P. Genetically modified mice and cognition. Curr Opin Neurobiol 1998, 8:272-280.
42. Marambaud P., Robakis N.K. Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. Genes Brain Behav 2005, 4:134-146.
43. Martin S.J., Grimwood P.D., Morris R.G. Synaptic plasticity and memory: an evaluation of the hypothesis. Annu Rev Neurosci 2000, 23:649-711.
44. Mattson M.P., Rychlik B., Chu C., Christakos S. Evidence for calcium-reducing and excito-protective roles for the calcium-binding protein calbindin-d28k in cultured hippocampal neurons. Neuron 1991, 6:41-51.
45. Mattson M.P., Cheng B., Baldwin S.A., Smith-Swintosky V.L., Keller J., Geddes J.W., Scheff S.W., Christakos S. Brain injury and tumor necrosis factors induce calbindin d-28k in astrocytes: evidence for a cytoprotective response. J Neurosci Res 1995, 42:357-370.
46. Mori F., Fukaya M., Abe H., Wakabayashi K., Watanabe M. Developmental changes in expression of the three ryanodine receptor mrnas in the mouse brain. Neurosci Lett 2000, 285:57-60.
47. Nagerl U.V., Novo D., Mody I., Vergara J.L. Binding kinetics of calbindin-d(28k) determined by flash photolysis of caged ca(2+). Biophys J 2000, 79:3009-3018.
48. Nishimura M., Yu G., St George-Hyslop P.H. Biology of presenilins as causative molecules for Alzheimer disease. Clin Genet 1999, 55:219-225.
49. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
50. Parent A., Linden D.J., Sisodia S.S., Borchelt D.R. Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1. Neurobiol Dis 1999, 6:56-62.
51. Parent A.T., Barnes N.Y., Taniguchi Y., Thinakaran G., Sisodia S.S. Presenilin attenuates receptor-mediated signaling and synaptic function. J Neurosci 2005, 25:1540-1549.
52. Poirier R., Jacquot S., Vaillend C., Soutthiphong A.A., Libbey M., Davis S., Laroche S., Hanauer A., Welzl H., Lipp H.P., Wolfer D.P. Deletion of the Coffin-Lowry syndrome gene rsk2 in mice is associated with impaired spatial learning and reduced control of exploratory behavior. Behav Genet 2007, 37:31-50.
53. Price D.L., Tanzi R.E., Borchelt D.R., Sisodia S.S. Alzheimer's disease: genetic studies and transgenic models. Annu Rev Genet 1998, 32:461-493.
54. Pybus R., Barnard E., Estibeiro P., Mullins J., MacLeod N. Enhanced long-term potentiation in the hippocampus of rats expressing mutant presenillin-1 is age related. Neurobiol Dis 2003, 12:212-224.
55. Raymond C.R., Redman S.J. Different calcium sources are narrowly tuned to the induction of different forms of LTP. J Neurophysiol 2002, 88:249-255.
56. Rybalchenko V., Hwang S.Y., Rybalchenko N., Koulen P. The cytosolic n-terminus of presenilin-1 potentiates mouse ryanodine receptor single channel activity. Int J Biochem Cell Biol 2008, 40:84-97.
57. Schapansky J., Olson K., Van Der Ploeg R., Glazner G. NF-kappaB activated by ER calcium release inhibits Abeta-mediated expression of chop protein: enhancement by AD-linked mutant presenilin 1. Exp Neurol 2007, 208:169-176.
58. Schneider I., Reverse D., Dewachter I., Ris L., Caluwaerts N., Kuiperi C., Gilis M., Geerts H., Kretzschmar H., Godaux E., Moechars D., Van Leuven F., Herms J. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J Biol Chem 2001, 276:11539-11544.
59. Selkoe D.J. The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. Neurol Clin 2000, 18:903-922.
60. Shimuta M., Yoshikawa M., Fukaya M., Watanabe M., Takeshima H., Manabe T. Postsynaptic modulation of AMPA receptor-mediated synaptic responses and LTP by the type 3 ryanodine receptor. Mol Cell Neurosci 2001, 17:921-930.
61. Smith I.F., Green K.N., LaFerla F.M. Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium 2005, 38:427-437.
62. Smith I.F., Hitt B., Green K.N., Oddo S., LaFerla F.M. Enhanced caffeine-induced Ca2+ release in the 3xtg-ad mouse model of Alzheimer's disease. J Neurochem 2005, 94:1711-1718.
63. St George-Hyslop P.H., Petit A. Molecular biology and genetics of Alzheimer's disease. C R Biol 2005, 328:119-130.
64. Steiner H. The catalytic core of gamma-secretase: presenilin revisited. Curr Alzheimer Res 2008, 5:147-157.
65. Stutzmann G.E., Caccamo A., LaFerla F.M., Parker I. Dysregulated ip3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci 2004, 24:508-513.
66. Stutzmann G.E., Smith I., Caccamo A., Oddo S., Parker I., Laferla F. Enhanced ryanodine-mediated calcium release in mutant ps1-expressing Alzheimer's mouse models. Ann N Y Acad Sci 2007, 1097:265-277.
67. Sun X., Beglopoulos V., Mattson M.P., Shen J. Hippocampal spatial memory impairments caused by the familial Alzheimer's disease-linked presenilin 1 m146v mutation. Neurodegener Dis 2005, 2:6-15.
68. Taufiq A.M., Fujii S., Yamazaki Y., Sasaki H., Kaneko K., Li J., Kato H., Mikoshiba K. Involvement of IP3 receptors in LTP and LTD induction in guinea pig hippocampal CA1 neurons. Learn Mem 2005, 12:594-600.
69. Toyoshima T., Yamagami S., Ahmed B.Y., Jin L., Miyamoto O., Itano T., Tokuda M., Matsui H., Hatase O. Expression of calbindin-d28k by reactive astrocytes in gerbil hippocampus after ischaemia. Neuroreport 1996, 7:2087-2091.
70. Tu H., Nelson O., Bezprozvanny A., Wang Z., Lee S.F., Hao Y.H., Serneels L., De Strooper B., Yu G., Bezprozvanny I. Presenilins form er Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell 2006, 126:981-993.
71. Zaman S.H., Parent A., Laskey A., Lee M.K., Borchelt D.R., Sisodia S.S., Malinow R. Enhanced synaptic potentiation in transgenic mice expressing presenilin 1 familial Alzheimer's disease mutation is normalized with a benzodiazepine. Neurobiol Dis 2000, 7:54-63.
72. Zucker R.S. Short-term synaptic plasticity. Annu Rev Neurosci 1989, 12:13-31.